Reading intermediate PGT-A signals and counseling patients through embryo transfer priority
Preimplantation genetic testing for aneuploidy (PGT-A) infers whole-embryo chromosome status from a tiny trophectoderm biopsy, sequenced by next-generation sequencing (NGS) at low coverage. Most results are unambiguous — but a meaningful fraction land in a gray zone between euploid and aneuploid, and interpreting that zone correctly has become one of the central challenges of modern genetic counseling in IVF.
A trophectoderm biopsy of 5–6 cells is lysed, its DNA whole-genome amplified, and sequenced at shallow depth (typically <1× coverage) across all 24 chromosome types. Read counts are binned along each chromosome and normalized against a reference; a chromosome present in the expected two copies produces a flat log2 ratio near 0, a trisomy produces a shifted flat line near +0.585, and a monosomy near −1.
Because the biopsy is a small, mixed pool of amplified DNA rather than a single cell, the copy-number caller is really measuring an average signal across those 5–6 cells. If every cell agrees, the line is flat and confident. If the cells disagree — some euploid, some aneuploid — the averaged signal sits at an intermediate, noisier level proportional to the fraction of abnormal cells in the biopsy.
A biopsy that is 30% aneuploid cells and 70% euploid cells produces a log2 ratio roughly 30% of the way toward the full trisomy/monosomy line — this intermediate signature is the entire basis for calling "mosaic" rather than clean euploid or aneuploid.
The same intermediate NGS signal can, in principle, arise from several different biological realities: (1) a true mosaic embryo with a genuine mixture of euploid and aneuploid cells in the biopsied tissue; (2) technical noise from uneven whole-genome amplification, low input DNA, or necrotic/degraded cells; or (3) a biopsy that happened to straddle a sharp clonal boundary within an otherwise non-mosaic embryo.
Laboratories set validated thresholds (commonly ~20% and ~80% abnormal-cell-equivalent signal) to separate "call as euploid," "call as mosaic," and "call as aneuploid" — but these thresholds are statistical conventions calibrated against reference cell-line mixtures, not a perfect biological measurement of the true cellular composition of the embryo.
Earlier PGT-A platforms (array-CGH, SNP arrays) had coarser resolution and effectively could not detect intermediate signals reliably, so embryos were binned as simply euploid or aneuploid. Modern high-resolution NGS platforms are sensitive enough to detect these intermediate signals reproducibly — which means mosaicism did not become more common, it became visible.
This technical advance created a new clinical category almost overnight: a meaningful share of embryos that are neither clearly transferable nor clearly discardable, requiring an entirely new counseling and prioritization framework that did not exist a decade ago.
Mosaicism is fundamentally different in origin from classic aneuploidy. A meiotic error (the cause of most aneuploidy, including Down syndrome) occurs during egg or sperm formation and is present in every single cell of the resulting embryo. A mitotic error occurs after fertilization, during the rapid cleavage divisions of the early embryo, and affects only the descendants of the one cell in which it happened.
During mitosis, sister chromatids are pulled to opposite spindle poles by microtubules attached at the kinetochore. Mitotic nondisjunction occurs when a chromosome fails to segregate correctly — both copies go to one daughter cell, leaving the other daughter with none for that chromosome (or a related error such as anaphase lag, where a chromosome is simply left behind and lost, or a post-anaphase micronucleus that is not properly reincorporated).
The result is one daughter cell with a normal chromosome complement and one daughter cell with a copy-number error, arising from a single, essentially random event in one specific cell cycle rather than a genome-wide problem.
Once a mitotic error founds an abnormal cell, every subsequent daughter cell in that lineage inherits the same imbalance — the abnormal clone expands in lockstep with the normal clone as the embryo continues dividing, preserving roughly the founding ratio through to the blastocyst stage.
The developmental timing of the error largely determines what fraction of the final blastocyst is abnormal. An error at the first cleavage division (2-cell stage) can produce a near 50/50 split between lineages. An error several divisions later, once the embryo already has 16 or 32 cells, produces a much smaller abnormal fraction because the abnormal clone has fewer remaining doublings to catch up.
Early cleavage-stage embryos are unusually prone to chromosome mis-segregation compared to virtually any other stage of human development — attributable to an immature spindle-assembly checkpoint, multipolar spindles, and reliance on maternally-supplied (not yet embryo-synthesized) cell-cycle machinery in the first few divisions.
Not all mosaicism looks the same under the microscope of NGS data. Clonal (or "true") mosaicism reflects one or a few discrete mitotic error events, producing one or two clearly defined abnormal cell lineages — this is the pattern most PGT-A counseling frameworks are built around.
Chaotic mosaicism, by contrast, reflects multiple independent errors across many cells, each with a different random chromosomal complement, and is generally associated with much lower developmental potential. Distinguishing clonal from chaotic mosaicism from a single 5–6 cell biopsy is difficult, which is part of why mosaic results are managed with caution rather than certainty.
Not all mosaic results carry equal risk. Two independent axes determine how a mosaic PGT-A result is graded and counseled: the level (what fraction of biopsied cells are abnormal) and the type (whether the imbalance affects an entire chromosome or only a segment of one). Use the sliders in the left panel to move a case between categories and watch the cell grid and classification respond.
Low-level mosaic (roughly 20–40% abnormal cells) and high-level mosaic (roughly 40–80% abnormal cells) are treated as clinically distinct categories, not just points on a continuum. Outcome data consistently show that low-level mosaic embryos implant and produce live births at rates approaching — though usually still somewhat below — euploid embryos, while high-level mosaic embryos show meaningfully lower implantation and higher miscarriage rates.
Below ~20%, most laboratories treat the signal as within the noise floor of the assay and issue a euploid call rather than a mosaic one. Above ~80%, the signal is treated as equivalent to a uniform aneuploid call, since so little euploid signal remains that the distinction has little practical meaning for transfer decisions.
A whole-chromosome mosaic aberration involves gain or loss of an entire chromosome in the abnormal cell lineage — the same scale of imbalance as classic trisomies like Down syndrome (trisomy 21). A segmental mosaic aberration involves only part of a chromosome (a duplication or deletion of one arm or a sub-region), generally affecting far fewer genes.
Segmental mosaic results are generally considered to carry a more favorable prognosis than whole-chromosome mosaic results at the same abnormal-cell level, because the smaller genomic imbalance is thought to be more compatible with normal development and more amenable to being outcompeted by the euploid cell lineage during further division.
A low-level, segmental mosaic result is generally considered the most favorable mosaic category for transfer consideration, while a high-level, whole-chromosome (or multiple-aneuploidy / "complex") mosaic result is generally considered the least favorable and lowest priority.
The visualization in this simulator represents the trophectoderm and inner cell mass as populations of individual cells, colored green for euploid and red for aneuploid, mixed in proportion to the "Mosaic Level" slider. This is a simplification for teaching purposes — no clinical test visualizes individual cells — but it illustrates the underlying biological reality that a single NGS copy-number value is really summarizing the mixed genetic makeup of many individual cells.
A blastocyst is not a uniform ball of identical cells. It has already differentiated into the trophectoderm (TE, ~150–250 cells, which forms the placenta and other extra-embryonic tissue) and the inner cell mass (ICM, a much smaller cluster of ~10–30 cells, which forms the fetus itself). PGT-A biopsies only the TE — never the ICM — for the practical reason that biopsying the ICM would risk damaging the cells that become the baby.
Because TE and ICM are separate lineages that diverged early in blastocyst formation, and because mitotic errors can occur at various points relative to that divergence, the fraction of abnormal cells measured in a TE biopsy is not guaranteed to equal the fraction of abnormal cells present in the ICM. An error arising before TE/ICM lineages split could appear in both compartments at similar levels; an error arising after the split, in one compartment only, could appear in the TE sample while the ICM remains entirely euploid — or vice versa.
This is the central epistemic limitation of PGT-A mosaicism testing: clinicians are counseling patients based on a proxy measurement of a tissue (TE, destined to become placenta) that is related to, but not identical with, the tissue that actually matters most for the resulting child (ICM, destined to become the fetus).
Some researchers have proposed that abnormal cells identified at the blastocyst stage may be progressively depleted during subsequent development — through preferential apoptosis of aneuploid cells, slower proliferation of abnormal clones relative to euploid ones, or allocation of abnormal cells preferentially to extra-embryonic tissue rather than the fetal lineage. Under this hypothesis, some mosaic embryos that would otherwise be viewed as compromised may "self-correct" toward a fully or predominantly euploid fetus.
This hypothesis is supported by some post-natal and prenatal follow-up data on transferred mosaic embryos showing normal fetal karyotypes, but it remains actively debated: it is difficult to distinguish true cellular self-correction from the alternative explanation that the original TE biopsy signal simply never reflected the ICM composition in the first place (i.e., there may have been nothing to "correct").
Whether self-correction is a real, active biological process or a sampling artifact of TE-only biopsy remains scientifically unresolved — but the clinical bottom line is the same either way: many mosaic-labeled embryos develop into healthy, chromosomally normal children.
Because the TE sample is an imperfect proxy for the ICM, genetic counselors frame a mosaic PGT-A result as a probabilistic risk adjustment rather than a diagnosis of the resulting child. Prenatal confirmatory testing (chorionic villus sampling, amniocentesis, or noninvasive prenatal testing followed by diagnostic confirmation) is routinely recommended for any pregnancy achieved from a mosaic embryo transfer, specifically because the original PGT-A result cannot, by itself, tell the patient what chromosome complement the fetus actually has.
This uncertainty is also why "prioritization" rather than "exclusion" has become the dominant clinical framework: rather than treating mosaic embryos as simply unusable, clinics rank them by estimated risk and offer them for transfer — particularly when no fully euploid embryo is available — accompanied by informed counseling and a prenatal testing plan.
When a patient has a choice among embryos, the transfer order matters. The PGDIS (Preimplantation Genetic Diagnosis International Society) 2019 guidance popularized a tiered prioritization framework for mosaic results, now widely adapted by IVF clinics and genetic counselors worldwide to standardize what had previously been ad hoc, clinic-by-clinic decision-making.
The core clinical principle is straightforward: transfer fully euploid embryos first whenever available. Only when no euploid embryo exists (or as an additional option a patient and physician choose together) does a mosaic embryo become a transfer candidate — and among available mosaic embryos, transfer in an order that reflects estimated risk, generally preferring lower abnormal-cell-percentage and segmental aberrations over higher-percentage and whole-chromosome aberrations.
Specific chromosome identity also matters clinically: mosaicism involving chromosomes compatible with live birth if fully aneuploid (e.g., sex chromosomes, chromosome 21) is generally viewed differently than mosaicism involving chromosomes essentially never compatible with live birth even in mosaic form.
Because no mosaic result carries a guaranteed outcome in either direction, genetic counseling for mosaic embryo transfer emphasizes shared decision-making rather than a simple accept/reject recommendation. Core elements typically include: explaining that the result reflects the TE biopsy only, not a diagnosis of the fetus; presenting embryo-specific and lab-specific outcome statistics where available; discussing the recommended prenatal confirmatory testing plan; and addressing that some embryos initially reported mosaic would, on repeat or independent testing, be reported differently — a reflection of assay and sampling variability, not necessarily a changing embryo.
Patients are also counseled that "no embryo available for transfer" and "only mosaic embryos available" are common, non-catastrophic scenarios in modern IVF — a direct consequence of higher-resolution NGS detecting a biological reality that older technology simply could not see.
Since mosaic embryo transfer began being offered in meaningful numbers in the mid-2010s, live births numbering in the thousands have now been reported globally, with the large majority showing normal postnatal karyotypes and normal early developmental outcomes, though long-term follow-up data are still comparatively limited relative to decades of euploid transfer outcome data.
Open questions actively studied include: whether specific chromosome-mosaicism combinations carry meaningfully different risk than the framework's broad level/type categories capture; whether repeat biopsy or non-invasive embryo assessment (e.g., analyzing spent culture media) could reduce reliance on a single TE sample; and how prioritization frameworks should be periodically revised as outcome datasets from mosaic transfers continue to mature.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| P1 — Euploid | Uniform normal signal, all chromosomes | No detectable abnormal-cell fraction | Highest priority — transfer first |
| P2 — Low-Level Segmental Mosaic | 20–40% abnormal, partial chromosome | Small genomic imbalance, minority cell fraction | Favorable mosaic prognosis |
| P3 — Low-Level Whole-Chromosome Mosaic | 20–40% abnormal, full chromosome | Larger genomic imbalance, minority cell fraction | Reasonable prognosis, counsel carefully |
| P4 — High-Level Segmental Mosaic | 40–80% abnormal, partial chromosome | Small imbalance, majority cell fraction | Lower priority, case-by-case discussion |
| P5 — High-Level Whole-Chromosome / Complex Mosaic | 40–80% abnormal or multiple aneuploidies | Large imbalance and/or multiple lineages | Lowest priority among mosaics |
| Not Prioritized — Aneuploid | >80% abnormal / uniform signal | Effectively no euploid cell contribution | Generally not recommended for transfer |